Advanced searches left 3/3

Multicenter Clinical Trial - PubMed

Summarized by Plex Scholar
Last Updated: 25 July 2022

* If you want to update the article please login/register

Beneficial Effect of Short-Term Supplementation of High Dose of Vitamin D3 in Hospitalized Patients With COVID-19: A Multicenter, Single-Blinded, Prospective Randomized Pilot Clinical Trial.

Vitamin D3 supplementation may be used prophylactically as an inexpensive and safe alternative to the current COVID-19 treatment regimen, according to the article. After 14 days of supplementation, serum 25D levels in the group who received 10,000IU/day were significantly elevated, particularly in overweight and obese patients, and the higher dose was well tolerated. A minority of the patients in our study had acute respiratory distress syndrome. In the participants assigned to the 10,000IU/day group and the 2,000IU/day group, the median length of hospital stay in these patients with ARDS was significantly different in both patients with ARDS. During hospitalization for COVID-19, the administration of 10,000IU/day vitamin D3 during hospitalization was safe, tolerable, and cost-effective, thus helping to reduce the prognosis during recovery.

Source link: https://doi.org/10.3389/fphar.2022.863587


Efficacy, Safety and Mechanism of Jinzhen Oral Liquid in the Treatment of Acute Bronchitis in Children: A Randomized, Double-Blind, Multicenter Clinical Trial Protocol.

Acute bronchitis is a common condition in pediatrics. Prolonged bronchitis may progress to chronic bronchitis. The influenza virus-related hypoxia or insufficient ventilation may be extreme, causing significant injury to patients and raising the burden on children and society. In previous clinical and basic research, Jinzhen Oral Liquid has been found to have a broad range of anti-inflammatory and antiviral effects, as well as a positive effect on children's AB. This study will determine the effectiveness, safety, and mechanism of JZOL in the treatment of AB in children. With a total of 1000 participants, the sample size for both the intervention group and the control group is 500 participants. The intervention group receives JZOL and Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution placebo, while the control group receives the AHCHOS and JZOL placebo. Quality control will be implemented at every stage of data administration and processing to ensure that all records are accurate and processed correctly. All statistical evaluations are carried out using a two-sided questionnaire, and p 0. 05 would be considered statistically significant. Examine: We hypothesized that children with AB can receive some health benefits from JZOL. This research investigates JZOL's clinical safety and safety, as well as the metagenomics and metabolomics of participant saliva, which were used to determine the mechanism of JZOL's anti-Abdominomics interaction against AB. This report, if successful, will give a high-quality evidence-based guide for the treatment of AB in children and future relevant studies.

Source link: https://doi.org/10.3389/fphar.2022.948236


Oral Valganciclovir Therapy in Infants Aged ≤2 Months with Congenital Cytomegalovirus Disease: A Multicenter, Single-Arm, Open-Label Clinical Trial in Japan.

Twenty-five babies aged u22642 months with congenital CMV disease affecting the central nervous system were enrolled and treated with VGCV for six months. The change in the whole blood CMV load before and after treatment was the primary endpoint. The mean change in the CMV DNA level in whole blood was -246. 0 IU/mL. Oral VGCV is a potential medical treatment for infants aged 0 to 224 days with congenital CMV disease.

Source link: https://doi.org/10.3390/jcm11133582


Lessons from a multicenter clinical trial with an approved wearable electrocardiogram: issues and practical considerations.

We undertook a multicenter clinical trial using an approved wearable patch ECG as an exploratory study. Two research centers were enrolled in healthy male adults. The approved ECGs were used for 6 hours, and pulse rates were measured without using conventional pulse oximetry at selected time points for correlation analysis. Overall, 77. 3 percent of heart rates were within the acceptable range. More than twice center 2 were found to be missing data in center 1. There was no correlation between heart rates measured by portable ECG and conventional pulse oximetry, indicating a lack of correlation.

Source link: https://doi.org/10.12793/tcp.2022.30.e7

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions